Hims & Hers Health has been embroiled in a lengthy battle with Novo Nordisk over the Danish drugmaker’s refusal to sell weight-loss drugs on its platform. Shares of the online pharmacy were rallying Monday on a report that Novo had agreed to sell its weight-loss drugs through Hims’ platform. Hims shares surged 53% to $24.10 ahead of the opening bell.